Recognition of carbohydrates on glycosylated molecules typically requires multivalent interactions with receptors. Monovalent forms of terminal saccharides engaged by the receptor binding sites typically display weak affinities in the mM range and poor specificity. In contrast, multivalent forms of the same saccharides are bound with strong affinity (10 ؊7 -10 ؊9 M) and significantly greater specificity. Although multivalency can readily account for increased affinity, the molecular basis for enhanced specificity is not well understood. We have examined the specificity of the cysteine-rich domain of the mannose/GalNAc-4-SO 4 receptor using monovalent and multivalent forms of the trisaccharide GalNAc␤1,4GlcNAc␤1,2Man␣ (GGnM) sulfated at either the C4 (S4GGnM) or C3 ( We previously demonstrated that glycoproteins such as LH 1 and thyrotropin bearing N-linked oligosaccharides terminating with ␤1,4-linked GalNAc-4-SO 4 are recognized by a receptor located in hepatic endothelial cells, the Man/GalNAc-4-SO 4 receptor, and are rapidly removed from the circulation (1-4) . Rapid clearance in conjunction with stimulated release from dense core storage granules in LH-producing cells located in the anterior lobe of the pituitary produce the episodic rise and fall in serum LH levels that is important for the expression of LH bioactivity in vivo. A novel feature of the Man/GalNAc-4-SO 4 receptor is its capacity to bind carbohydrate moieties terminating with Man and GalNAc-4-SO 4 at physically distinct domains that are not structurally related. The binding site for GalNAc-4-SO 4 is located in the cysteine-rich domain found at the N terminus of the Man/GalNAc-4-SO 4 receptor (5). The Cys-rich domain is a member of the ␤-trefoil family of proteins that includes proteins such as acidic fibroblast growth factor. The binding site is a neutral pocket that accommodates the sulfate group, which accounts for the major interactions with the protein (6). Inhibition and modeling studies with monovalent ligands have indicated that the binding site in the Cys-rich domain can also accommodate saccharides with terminal Gal or GalNAc when the sulfate is located at C3 rather than C4 (6, 7).
with ␤1,4-linked GalNAc-4-SO 4 are recognized by a receptor located in hepatic endothelial cells, the Man/GalNAc-4-SO 4 receptor, and are rapidly removed from the circulation (1) (2) (3) (4) . Rapid clearance in conjunction with stimulated release from dense core storage granules in LH-producing cells located in the anterior lobe of the pituitary produce the episodic rise and fall in serum LH levels that is important for the expression of LH bioactivity in vivo. A novel feature of the Man/GalNAc-4-SO 4 receptor is its capacity to bind carbohydrate moieties terminating with Man and GalNAc-4-SO 4 at physically distinct domains that are not structurally related. The binding site for GalNAc-4-SO 4 is located in the cysteine-rich domain found at the N terminus of the Man/GalNAc-4-SO 4 receptor (5). The Cys-rich domain is a member of the ␤-trefoil family of proteins that includes proteins such as acidic fibroblast growth factor. The binding site is a neutral pocket that accommodates the sulfate group, which accounts for the major interactions with the protein (6) . Inhibition and modeling studies with monovalent ligands have indicated that the binding site in the Cys-rich domain can also accommodate saccharides with terminal Gal or GalNAc when the sulfate is located at C3 rather than C4 (6, 7) .
The latter observations were unexpected because we had reported that bovine serum albumin substituted with 6 -8 molecules of SO 4 -4-GalNAc␤1,4GlcNAc␤1,2Man␣ (S4GGnM-BSA) is removed from the circulation at a rate that is at least 12-fold greater than that seen for bovine serum albumin substituted with 6 -8 molecules of SO 4 -3-GalNAc␤1,4GlcNAc␤1,2Man␣ (S3GGnM-BSA). Furthermore, isolated hepatic endothelial cells do not bind and internalize S3GGnM-BSA, and the purified Man/GalNAc-4-SO 4 receptor does not display significant binding of S3GGnM-BSA in precipitation assays (2, 3) . We have recently determined that the Man/GalNAc-4-SO 4 receptor must be dimeric and engage at least two terminal GalNAc-4-SO 4 moieties on separate oligosaccharides to mediate uptake by hepatic endothelial cells with a K d of 1.63 ϫ 10 Ϫ7 M (8) . These observations raise the possibility that the Man/GalNAc-4-SO 4 receptor may display significantly greater specificity when binding ligands with multiple terminal sulfated saccharide moieties than when binding monovalent forms of the same ligands. We have examined this possibility using well characterized ligands of known valency and structure. Our studies demonstrate that the Man/GalNAc-4-SO 4 receptor displays greater specificity for multivalent forms of the same structures than for monovalent forms and that this can be explained best by the presence of favorable and unfavorable conformations of the trisaccharides for binding to the Cys-rich domain. Remarkably, inhibition constants obtained with the monovalent forms of these trisaccharides are not predictive of the properties of multivalent forms of the same structures. 4 -Fc(Mu0) (the transmembrane and cytosolic domains are replaced by the hinge, C H 2, and C H 3 domains of * This work was supported by National Institutes of Health Grants R37-CA21923 and R01-DK41738. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
EXPERIMENTAL PROCEDURES

Materials-Man/GalNAc-4-SO
‡ To whom correspondence should be addressed. human IgG1), Man/GalNAc-4-SO 4 -Fc(Mu10) (deletion of the fibronectin type II repeat and carbohydrate recognition domains (CRDs) 1-3 from Mu0), and Man/GalNAc-4-SO 4 -Fc(Mu11) (deletion of the fibronectin type II repeat and CRDs 1-8 from Mu0) were prepared as described (5) . 3Ј-SO 4 -Lewis X (3Ј-O-SO 3 Gal␤1,4(Fuc␣1,3)GlcNAc) was from Calbiochem. S4GGnM-MCO, S3GGnM-MCO, and their BSA conjugates, S4GGnM-BSA and S3GGnM-BSA, were prepared as described (9) . The LH␣ subunit was supplied by the National Hormone and Pituitary Program (NIDDK, National Institutes of Health) and A. F. Parlow.
Surface Plasmon Resonance Analysis-Surface plasmon resonance (SPR) analyses were performed on an Amersham Pharmacia Biotech BIACORE 2000 instrument as described previously (8) . For studies using immobilized the Cys-rich domain, a predetermined amount of Man/GalNAc-4-SO 4 -Fc(Mu11) was allowed to bind to protein A (Pierce), which had been covalently attached to a CM5 sensor chip. The amount of Mu11 bound was monitored by SPR. No detectable dissociation of Mu11 from protein A was observed under the conditions of the assay. For inhibition studies the bovine LH␣ subunit (685 nM) was passed over the chip at a flow rate of 5 l/min for 300 s in the presence of increasing concentrations of saccharide inhibitors. The amount of LH␣ bound at equilibrium was used to generate inhibition curves that were analyzed by nonlinear regression using PRISM software (version 2.0). K i values were calculated from the concentration of inhibitor that effected 50% inhibition. For glycoconjugate binding studies, differing concentrations of S4GGnM-BSA and S3GGnM-BSA were passed over immobilized Mu11 at a flow rate of 5 l/min for 10 min. Dissociation was initiated at 10 min by elution with TBS buffer (20 mM Tris⅐HCl, pH 7.4, 150 mM NaCl) ϩ 0.005% (w/v) surfactant P20 or TBS buffer ϩ 0.005% surfactant P20 containing 1 mM GalNAc-4-SO 4 .
Binding of Mu11 to immobilized S4GGnM-BSA and S3GGnM-BSA was also monitored using SPR. Similar amounts of S4GGnM-BSA and S3GGnM-BSA were attached covalently to a BIACORE CM5 sensor chip through primary amine groups using the amine coupling kit provided by the manufacturer. The amount of S4GGnM-BSA and S3GGnM-BSA conjugated was determined from the increase in response units. Mu11 was passed over immobilized BSA conjugates at a flow rate of 5 l/min for 10 min. The amount of Mu11 bound at equilibrium was used to generate saturation curves that were analyzed by nonlinear regression using PRISM software (version 2.0).
Mole ratios were determined by dividing the change in response unit values obtained for immobilized or bound glycoproteins by their respective molecular weights. The molecular weights utilized were: LH␣, 14,600; Mu11, 98,100; S4GGnM-BSA, 73,100; and S3GGnM-BSA, 73,100. The values calculated for S4GGnM-BSA and S3GGnM-BSA reflect the presence of 7 mol of sulfated trisaccharide conjugated/mol of BSA and are consistent with their mobility when examined by SDSpolyacrylamide gel electrophoresis (data not shown).
Equilibrium Dialysis Studies-3Ј-SO 4 -Lewis X and a glucose pentasaccharide (Glc5) prepared from dextran by mild acid hydrolysis (10) were derivatized with 9-aminopyrene-1,4,6-trisulfonic acid (APTS) by reductive amination as described (11) . Binding was performed in a two-chamber Teflon Micro-Equilibrium dialyzer (Amika, Inc.) utilizing ultrathin 10,000-dalton cut-off membranes (The Nest Group, Inc.). One chamber contained either 10 M Mu11 (based on M r ϭ 98,100) or BSA (1 mg/ml) in 25 l of TBS buffer. The second chamber contained 0.1-10 nmol of 3Ј-SO 4 -Lewis X -APTS and Glc5-APTS in 25 l of TBS buffer. Dialysis was allowed to proceed for 96 h at 4°C. Thereafter, 2-l aliquots were removed from each side of the membrane, and the amounts of 3Ј-SO 4 -Lewis X -APTS and Glc5-APTS were quantitated by capillary electrophoresis using an N-CHO-coated capillary column on a Beckman P/ACE 5000 and laser-induced fluorescence for detection as described by the manufacturer. The Glc5-APTS was used to normalize the amount of 3Ј-SO 4 -Lewis X -APTS because it did not demonstrate any binding to Mu11 or BSA.
Monosaccharide Composition Analysis of BSA Conjugates-Quantitative analysis of the sugar constituents of the sulfated glycoconjugates was performed according to the method developed by Chen et al. (12) . S4GGnM-BSA and S3GGnM-BSA were hydrolyzed with 2.0 N trifluoroacetic acid to release their constituent sugars. After amino sugar Nacetylation with acetic anhydride in sodium carbonate, the released monosaccharides were derivatized with APTS by reductive amination. Capillary electrophoresis was performed using a fused silica column in 120 mM MOPS buffer, pH 7.0, on a Beckman P/ACE 5000 (13) . The APTS monosaccharides were identified and quantitated using laserinduced fluorescence and comparison with monosaccharide standards.
Solution Binding Assays-Affinity-purified Man/GalNAc-4-SO 4 I-BSA complexes were precipitated by the addition of 1.5 ml of ice-cold 10% polyethylene glycol-8000 (Sigma) and collected on Whatman GF/C filter discs as described (3). (Table I) . The similar K i values obtained for GalNAc-4-SO 4 and S4GGnM indicate that recognition is directed almost exclusively at the terminal sulfated monosaccharide. The K i value determined for S3GGnM is half that obtained for S4GGnM. Thus, for the monovalent trisaccharide SO 4 -GalNAc␤1,4GlcNAc␤1, 2Man␣-MCO location of the sulfate at the C3 hydroxyl as compared with the C4 hydroxyl of the terminal, GalNAc enhances interaction with the binding site in the Cys-rich domain.
RESULTS
Specificity of the Cys-rich Domain for Monovalent Ligands-We
We (Fig. 2) . The K d obtained by equilibrium dialysis is in good agreement with the K i of 29.7 M obtained by inhibition studies on the BIACORE as described above (Table I) . Furthermore, in agreement with our previous studies (8) and the crystallographic analysis (6), each Cys-rich domain has a single binding site for a sulfated saccharide.
Specificity of the Cys-rich Domain for Multivalent Ligands-We previously determined the dissociation constant for S4GGnM-BSA is 0.013 M for Man/GalNAc-4-SO 4 -Fc(Mu0) and Man/GalNAc-4-SO 4 -Fc(Mu11) (5) . The assay utilized for these determinations relied on polyethylene glycol-mediated precipitation of S4GGnM-125 I-BSA complexed to Mu0 or Mu11. We determined inhibition constants for S4GGnM-BSA and S3GGnM-BSA using S4GGnM-125 I-BSA and Man/GalNAc-4-SO 4 -Fc(Mu10) (Fig. 3) . Mu10 was used because it is secreted more efficiently after transfection than Mu0 and is more efficiently precipitated by 10% polyethylene glycol-8000 than Mu11. S4GGnM-BSA has a K i of 0.013 M, whereas S3GGnM- BSA has a K i of 0.170 M (Table I) . This results in a 2000-fold change in the affinity for S4GGnM-BSA as compared with monovalent S4GGnM (0.013 versus 25.8 M) and a 95-fold change in affinity for S3GGnM-BSA as compared with the monovalent S3GGnM (0.170 versus 16.2 M). Even though the K i for S4GGnM is 1.6-fold greater than the K i for S3GGnM, the K i for S3GGnM-BSA is 13-fold greater than the K i for S4GGnM-BSA. Thus, the Man/GalNAc-4-SO 4 
Kinetics for Binding S4GGnM-BSA and S3GGnM-BSAThe above inhibition studies alone did not provide insight to the molecular basis for the difference in specificity for monovalent and multivalent forms of the same trisaccharides. We therefore used SPR to examine the kinetics of S4GGnM-BSA (Fig. 4A ) and S3GGnM-BSA (Fig. 4B) binding to immobilized Mu11. At a concentration of 400 nM, the binding of S4GGnM-BSA rapidly reaches saturation. Elution with buffer devoid of S4GGnM-BSA beginning at 700 s results in little or no dissociation. The highest amount of S4GGnM-BSA bound yields a mole ratio of 0.34 mol S4GGnM-BSA/mol of Mu11 or 0.17 mol S4GGnM-BSA/mol of Cys-rich domain. This is equal to a Cysrich domain/S4GGnM-BSA mole ratio of 5.9, which is a value close to the theoretical maximum of 6.7 based on the number of trisaccharides conjugated to the BSA (see below) and a single binding site for terminal GalNAc-4-SO 4 /Cys-rich domain. Further, this indicates that the slow dissociation rate is a result of multivalent binding. At a concentration of 8 nM S4GGnM-BSA (Fig. 4A ) the amount of S4GGnM-BSA bound increases throughout the binding phase of the experiment. Because of the lack of significant dissociation of the bound ligand, if given sufficient time the amount of S4GGnM-BSA bound to Mu11 would attain the same maximum as was seen with 400 nM S4GGnM-BSA. Further evidence for the contribution of multivalency to the slow dissociation rate was obtained by co-injection of 1 mM GalNAc-4-SO 4 during the dissociation phase (Fig.  4C) . The S4GGnM-BSA was rapidly and completely dissociated, indicating that the equilibrium at individual GalNAc-4-SO 4 binding sites is rapid. The dissociation rate in the presence of 1 mM GalNAc-4-SO 4 is so rapid that the dissociation rate could not be determined by SPR.
S3GGnM-BSA was also bound by immobilized Mu11 (Fig.  4B) . The amount of S3GGnM-BSA bound was less than the amount of S4GGnM-BSA bound at the same concentration (compare 400-nM concentrations in Fig. 4, A and B) . However, the amount of S3GGnM-BSA bound to Mu11 continues to increase with time. Furthermore, little or no dissociation of S3GGnM-BSA is observed when elution with buffer free of S3GGnM-BSA is initiated at 700 s. Thus, as was seen for S4GGnM-BSA, complexes formed with S3GGnM-BSA are multivalent and highly stable. Furthermore, bound S3GGnM-BSA is rapidly dissociated from Mu11 in the presence of 1 mM GalNAc-4-SO 4 (Fig. 4C) . Given sufficient time and/or increased concentrations of S3GGnM-BSA, maximal amounts of binding equal to those obtained with S4GGnM-BSA can be attained (data not shown).
Because neither S4GGnM-BSA nor S3GGnM-BSA dissociates at a significant rate from the immobilized Mu11, the results shown in Fig. 4, A and B , indicate that at identical concentrations the association rate for S3GGnM-BSA is considerably slower than for S4GGnM-BSA. A difference in the ratio of trisaccharide conjugation to BSA was excluded as an explanation for the different rates by determining the mole ratio of trisaccharide to BSA for each conjugate. After acid hydrolysis, the released monosaccharides were derivatized with APTS and quantitated by capillary electrophoresis using a laser-induced fluorescence detector (data not shown). The mole ratio of trisaccharide to BSA was 6.73 for S4GGnM-BSA and 6.75 for S3GGnM-BSA, which is in agreement with the analyses performed at the time of synthesis. Thus, the different characteristics seen for S4GGnM-BSA and S3GGnM-BSA binding to immobilized Mu11 reflect a significantly slower association rate for S3GGnM-BSA than for S4GGnM-BSA.
The multivalent nature of the binding of S4GGnM-BSA and I-BSA was incubated with Man/GalNAc-4-SO 4 -Fc(Mu10), and complexes were precipitated by the addition of 10% polyethylene glycol-8000. Increasing amounts of either S3GGnM-BSA (q) or S4GGnM-BSA (E) were added to generate the inhibition curves shown. K i values were determined as summarized in Table I. S3GGnM-BSA to immobilized Mu11 and the consequent lack of dissociation prevent kinetic analyses. We therefore used SPR to characterize the binding of Mu11 to identical concentrations of immobilized S4GGnM-BSA and S3GGnM-BSA. Although the immobilized BSA conjugates are multivalent, the Man/GalNAc-4-SO 4 -Fc(Mu11) chimera is bivalent and can only engage two terminal sulfated GalNAc moieties. The results of these analyses are shown in Figs. 5 and 6 and summarized in Table II . Mu11 reaches equilibrium rapidly when binding to either immobilized S4GGnM-BSA or S3GGnM-BSA (Fig. 5) . Mu11 bound to immobilized S4GGnM-BSA with a K d of 3.90 M and bound to immobilized S3GGnM-BSA with a K d of 3.93 M. However, Mu11 bound to S4GGnM-BSA with a B max of 0.74 mol/mol and bound to S3GGnM-BSA with a B max of 0.09 mol/mol (see Fig. 6 and Table  II) . Thus, even though Mu11 binds to both conjugates with a similar affinity under these conditions, there is an 8-fold difference in the amount of Mu11 bound at saturation. This is true even though the number and concentration of terminal sulfated saccharides are essentially identical. DISCUSSION Our analyses demonstrate that inhibition constants obtained with monovalent ligands do not necessarily predict the properties of multivalent forms of the same ligands. This study provides new insights into the basis for the remarkable difference in specificity displayed by the Man/GalNAc-4-SO 4 receptor for multivalent as compared with monovalent ligands. The clearance studies we performed in the rat (1), as well as subsequent analyses with the isolated hepatic endothelial cells (2) and the purified Man/GalNAc-4-SO 4 receptor (3), indicated that this receptor displays specificity for the location of the sulfate on terminal ␤1,4-linked GalNAc in the context of the sequence GalNAc␤1,4GlcNAc␤1,2Man␣. The recent report (7) that monovalent saccharides with a sulfate located at the C3 hydroxyl of Gal have K i values similar to those of monovalent structures with the sulfate located at the C4 hydroxyl of Gal or GalNAc seemed to contradict these observations. The studies we have presented here demonstrate that the Man/GalNAc-4- were injected at a flow rate of 5 l/min, and the amount of binding was monitored by SPR. After 700 s, buffer without S4GGnM-BSA or S3GGnM-BSA was passed over the chip to monitor dissociation. C, S4GGnM-BSA (80 nM) and S3GGnM-BSA (400 nM) were injected as above except that 1 mM GalNAc-4-SO 4 was co-injected during the dissociation phase.
SO 4 receptor displays far greater specificity for multivalent ligands than would be predicted on the basis of binding constants obtained for monovalent forms of the same ligands.
Each Cys-rich domain is able to engage a single terminal sulfated monosaccharide. In agreement with the studies of Leteux et al. (7) and Liu et al. (6, 14) , monovalent forms of the trisaccharide GalNAc␤1,4GlcNAc␤1,2Man␣-MCO sulfated at either the C3 or C4 hydroxyl of the terminal GalNAc are bound with similar affinities of 16.2 and 25.8 M, respectively. How can we, therefore, account for the dissociation constants of 0.170 and 0.013 M obtained for S3GGnM-BSA and S4GGnM-BSA, respectively? Investigators have previously observed greater specificity on the part of lectins for polyvalent ligands as compared with their monovalent counterparts (15) (16) (17) (18) (19) (20) (21) (22) . The specificity for multivalent ligands has been attributed to a requirement for unique spacing patterns (15) (16) (17) (18) , secondary protein-protein and protein-carbohydrate interactions (19, 20) , and amplification in the polyvalent state of small differences in the affinities between monovalent forms (21) . One prediction of a model in which small differences in affinity of monovalent ligands are amplified in the polyvalent state is that the affinities obtained for Mu11 binding to immobilized S4GGnM-BSA and S3GGnM-BSA would differ but that the B max obtained at saturation would be the same. This is not the case because Mu11 binds to immobilized S4GGnM-BSA and S3GGnM-BSA with the same affinity but with an 8-fold difference in B max at saturation. The behavior seen in Fig. 6 is explicable if the trisaccharide S3GGnM exists in two distinct conformations, only one of which is favorable for binding (see Fig. 7A ). The crystal structures of the Cys-rich domain binding 3Ј-SO 4 Lewis a (3Ј-(SO 4 -Gal␤1,3(Fuc␣1,4) GlcNAc)) and 3Ј-SO 4 -Lewis X indeed display significant differences in the structure of the carbohydrate, suggesting that one or both of the 3Ј-sulfated oligosaccharides undergo a conformational change when binding to the Cys-rich domain (14) . The N-acetyl present on the GalNAc-3-SO 4 may require an even greater change in conformation to allow binding. Formation of stable complexes requires the simultaneous engagement of two terminal GalNAc-3-SO 4 moieties by the bivalent Mu11. If only a small portion of the S3GGnM is in a form favorable for binding at any point in time, and all of the S4GGnM is in a favorable form for binding, the effective concentration of S3GGnM-BSA would appear to be a fraction of that of S4GGnM-BSA. However, when binding does occur to the favorable form of S3GGnM, it would have the same properties as the binding to S4GGnM-BSA. Hence the two would have the same K d but different B max values. Differences in the contribution of conformational entropy (23) , defined as the contribution of entropy arising from a difference in the number of conformations available before complexation and after complexation, are the most likely basis for the 13-fold difference in the K i values obtained for S4GGnM-BSA and S3GGnM-BSA. When S3GGnM-BSA and S4GGnM-BSA bind to immobilized Mu11, this difference is manifested as a slow association rate for S3GGnM-BSA as compared with S4GGnM-BSA (Fig. 4) . Once a sufficient number of terminal sulfated saccharides are engaged, the multivalent interaction results in a negligible dissociation rate for both S3GGnM-BSA and S4GGnM-BSA (see Fig. 7B ). As a result, if given sufficient time S3GGnM-BSA will reach the same maximal level of binding as S4GGnM-BSA when examined on the BIACORE. Equilibration at individual binding sites is rapid, however, because both S3GGnM-BSA and S4GGnM-BSA dis- Table II . RU, response units (2) . Radiolabeled S4GGnM-BSA is rapidly removed from the blood (t1 ⁄2 ϭ 1.3 min), whereas S3GGnM-BSA is removed slowly (t1 ⁄2 ϭ 15.3 min). Thus, the 12-fold difference in clearance rate correlates well with the 13-fold difference in K i . Furthermore, S4GGnM-BSA but not S3GGnM-BSA is bound and internalized by isolated hepatic endothelial cells (2) . Because the GalNAc-4-SO 4 -specific form of the Man/GalNAc-4-SO 4 receptor in hepatic endothelial cells exists as a dimer (8) , binding two terminal GalNAc-3-SO 4 -moieties is not likely to produce a sufficiently stable complex to mediate internalization. In addition, the interaction with a greater number of terminal GalNAc-3-SO 4 -moieties by bridging between dimeric GalNAc-4-SO 4 receptors is likely a slow process relative to the rate of receptor internalization. As a result ligands terminating with Gal or GalNAc sulfated at the C3 hydroxyl are not likely to represent ligands for the Man/GalNac-4-SO 4 receptor in vivo.
Soluble forms of the Man/GalNAc-4-SO 4 receptor have been reported in the circulation and are thought to arise as a result of proteolytic digestion (24) . These soluble forms of the Man/ GalNAc-4-SO 4 receptor would not be likely to bind terminal GalNAc-4-SO 4 , GalNAc-3-SO 4 , or Gal-3-SO 4 unless they remain dimeric or are in some manner multimerized. The amount of GalNAc-3-SO 4 or Gal-3-SO 4 that would be required would be at least 8-fold higher than GalNAc-4-SO 4 . Whether the soluble forms of the Man/GalNAc-4-SO4 receptor in serum exist as dimeric or monomeric molecules remains to be addressed.
Our studies demonstrate that although the binding site of the Cys-rich domain of the Man/GalNAc-4-SO 4 receptor can accommodate a number of different sulfated monosaccharides as monovalent ligands, it displays much more highly restricted specificity when simultaneously engaging two or more terminal sulfated GalNAc or Gal moieties. That this specificity is attained through differences in conformational entropy is remarkable and may apply to other instances in which multivalent ligands are recognized by lectins with greater specificity than the same monovalent ligands. The affinity and specificity of the Man/GalNAc-4-SO 4 receptor for oligosaccharides terminating with ␤1,4-linked GalNAc-4-SO 4 are essential for regulating the half-life of LH in the circulation throughout the ovulatory cycle including the preovulatory surge. The ability to ignore other ligands whether monovalent or multivalent assures that the clearance of LH will be maintained even if other sulfated ligands are present in the blood. Precisely how multivalent forms of S3GGnM are excluded from binding while multivalent forms of S4GGnM are not excluded will require real-time analysis of such ligands in the presence of dimeric Cys-rich domains. Models of oligosaccharides terminating with GalNAc-4-SO 4 and GalNAc-3-SO 4 reveal marked differences in their three-dimensional structures that would potentially have a major impact on access to the binding site on the Cys-rich domain. This represents a highly novel mechanism to dictate the specificity of carbohydrate receptors for complex multivalent saccharide structures in vivo.
